Selected by the European Commission through the EuroNanoMed programme, this project aims to improve CAR T cell therapy using messenger RNA (mRNA). Its aim is to make the therapeutic effect more sustained thanks to gold nanoparticles that will control the release of mRNAs. The project is coordinated by the ICN2 and has the experience of Hospital Clínic de Barcelona – IDIBAPS, IRCCS – Istituto di Ricerche Farmacologiche “Mario Negri” in Milan and Tel Aviv University in Tel Aviv.
